End-to-End Clinical Trial & CRO Services in Taiwan
Enabling Risk-Based GxP Compliance with Confidence
Taiwan is a leading country in pharmaceuticals and biotechnology, supported by a robust manufacturing sector, government innovation initiatives, and increasing healthcare needs. The Taiwan Food and Drug Administration (TFDA) regulates this market by enforcing ICH-GCP guidelines and PIC/S GMP standards, ensuring alignment with top international standards through its membership in ICH and PIC/S.
A key advantage for global companies is TFDA’s acceptance of foreign clinical data and recognition of MDSAP audit reports for medical devices. The government has committed over NT$24 billion (approx. USD 750 million) through 2029 to enhance domestic drug manufacturing resilience and growth. As a PIC/S member and active WHO collaborator, Taiwan is a strategic gateway to Asian markets. Zenovel provides regulatory and scientific solutions to ensure GCP/GMP compliance and expedite market access in Taiwan’s life sciences sector.
Good Clinical Practice (GCP) Services in Taiwan
Supporting Regulatory-Ready Clinical Trials with Robust GCP Oversight
Taiwan is a key player in clinical research, holding full membership in the ICH and PIC/s. The TFDA regulates pharmaceutical activities under GCP regulations aligned with ICH E6(R3) guidelines. A new “Streamlined Review Procedure for Multicenter Drug Clinical Trials” was implemented in September 2025 to expedite approvals and allow the use of foreign clinical data for marketing. Recent updates to the GCP Inspection Checklist improve inspection readiness, establishing Taiwan as a strategic hub for drug development in Asian markets.
Zenovel offers specialized GCP services in Taiwan, ensuring alignment with TFDA regulations and ICH E6(R3) standards, aiding pharmaceutical and biotech companies in achieving compliance and inspection readiness.
- GCP compliance & audit services – risk‑based quality management, CAPA handling, TMF review, and full support for TFDA’s streamlined review procedures.
- Inspection readiness & sponsor oversight – mock audits, documentation control, and site/vendor compliance to ensure flawless regulatory evaluations.
Zenovel enhances your clinical trial compliance in Taiwan by aligning with TFDA’s adoption of ICH E6(R3) and fostering international regulatory cooperation.
Computer System Validation (CSV) Services for GCP Compliance
We offer CSV Expertise for GCP Compliance and Audit‑Ready Clinical Systems in Taiwan.
Taiwan has established a high-standard clinical research environment as a full member of the ICH and the PIC/S. The TFDA enforces GCP and GMP in line with ICH E6(R3) and PIC/S standards, with a strong focus on the validation of computerized systems in GxP settings. Zenovel offers Computer System Validation (CSV) Services to assist pharmaceutical companies, CROs, and clinical research organizations in maintaining regulatory compliance and ensuring data integrity.
CSV for GCP/GxP Compliance – risk assessments, validation planning, protocol development (IQ/OQ/PQ), and full documentation.
System validation for clinical, laboratory & enterprise platforms – EDC, CTMS, LIMS, eTMF, ERP.
Data integrity, audit trail & electronic record compliance – aligned with TFDA expectations and global standards.
Audit‑ready validation – scalable, integrated with your quality strategy.
Zenovel collaborates with IT, QA, and clinical teams to minimize validation delays and enhance compliance, ensuring preparedness for TFDA inspections and global audits. Engage with Zenovel for expert CSV support in Taiwan to bolster GCP compliance.
GCP Audit Services for Clinical Trial Quality and Regulatory Compliance
Building Trust in Clinical Research Through Quality-Focused GCP Audits
Taiwan’s clinical trial environment is regulated by the TFDA, a full member of ICH and PIC/S, ensuring adherence to the “Regulations for Good Clinical Practice” in alignment with ICH E6(R3) guidelines. TFDA’s acceptance of foreign clinical data positions Taiwan as a key player in global drug development. Zenovel offers GCP Audit Services in Taiwan to support pharmaceutical firms, sponsors, and CROs in achieving regulatory compliance and maintaining clinical trial quality.
Audit – site audits, sponsor audits, vendor audits, and system‑level quality reviews.
Alignment – ICH E6(R3) guidelines, TFDA regulations, and WHO GCP standards.
Key assessments—protocol adherence, informed consent processes, documentation accuracy, and data integrity.
CAPA & readiness – CAPA development, risk‑based quality improvement, inspection readiness planning.
Our experienced auditors conduct detailed assessments to identify compliance gaps, strengthen operational processes, and protect patient safety. With deep expertise in global regulatory requirements, Zenovel delivers reliable GCP compliance audits tailored to your study’s needs.
CRO Setup & Upgradation Services for Clinical Excellence
Advancing Clinical Research Standards Through Modern CRO Development Strategies
Ensuring GCP compliance, risk-based quality management, and inspection readiness is critical for CROs. Zenovel provides CRO Setup & Upgradation Services to assist both new and established clinical research organizations in developing efficient and compliant operations.
Zenovel provides CRO setup and upgrade services in Taiwan, assisting clinical research organizations in establishing efficient, compliant, and scalable operations.
CRO setup – strategic planning, infrastructure development, SOP creation, and QMS implementation aligned with TFDA, ICH E6(R3), and WHO GCP standards.
CRO upgradation—workflow optimization, GCP‑compliant documentation, risk‑based monitoring (RBM) integration, vendor management frameworks, and mock TFDA inspections.
Inspection readiness & compliance – audit preparation, CAPA implementation, and continuous compliance improvement.
We collaborate with your leadership, QA, and clinical teams to enhance research capabilities, mitigate compliance risks, and promote sustainable growth.
PK-Stat Review Services for Accurate Clinical Data Analysis
Supporting evidence-based decisions with accurate clinical data analysis
Taiwan’s clinical research framework, governed by the TFDA as a full ICH member, enforces ICH E6(R3) GCP and statistical guidelines. Precision in pharmacokinetic and biostatistical data is crucial to avoid impacting dosing and regulatory outcomes. Zenovel provides reliable PK-Stat Review Services to assist pharmaceutical companies, CROs, and research organizations in ensuring accurate clinical data evaluation and regulatory compliance.
- PK/PD analysis – non‑compartmental analysis (NCA), population PK modeling, dose‑response evaluation.
- Alignment – TFDA expectations, ICH guidelines, and global standards (FDA, EMA).
- Data integrity – clinical biostatistics review, CDISC compliance (SDTM/ADaM), submission‑ready outputs.
- Regulatory support – independent review for bioequivalence studies, clinical trials, and NDA/ANDA submissions.
Zenovel leverages scientific expertise and advanced analytics to enhance data reliability and inform regulatory decisions, offering specialized PK-Stat review and clinical data analysis support in Taiwan.
Pre-Inspection Readiness Services for GCP Compliance and Regulatory Success
Strengthening Trial Readiness for Successful Regulatory Inspections
Regulatory inspections are essential in Taiwan’s clinical trial environment under the TFDA, particularly following updates to the GCP Inspection Checklist that have raised inspection readiness expectations. Proactive preparation by sponsors, CROs, and sites is crucial, with Zenovel providing Pre-Inspection Readiness Services to aid in preparing for TFDA inspections and clinical trial audits.
- Gap assessments & mock inspections – TFDA‑style simulated inspections.
- Documentation reviews & quality system evaluations – informed consent, protocol adherence, data integrity, vendor oversight.
- CAPA effectiveness review & inspection response strategy.
- Staff training – inspection preparedness and real‑time response.
Zenovel’s proactive approach identifies compliance risks early and implements corrective actions, enhancing operational efficiency and quality systems to ensure successful inspection outcomes. Partner with Zenovel to improve inspection readiness and achieve confident regulatory compliance in Taiwan.
Risk-Based Monitoring (RBM) Services for Efficient and Compliant Clinical Trials
Enhancing trial quality through targeted oversight and data-driven monitoring
Traditional monitoring methods often hinder trials and overlook essential risks. Taiwan’s clinical research landscape, regulated by the TFDA, adhering to ICH E6(R3) guidelines, requires enhanced, risk-proportionate oversight. The TFDA’s revised “GCP Inspection Checklist” and streamlined review processes highlight the need for proactive quality management. Zenovel offers specialized Risk-Based Monitoring (RBM) Services in Taiwan to assist pharmaceutical companies, sponsors, and CROs in enhancing trial quality, efficiency, and regulatory compliance.
- Centralized monitoring & key risk indicator (KRI) development
- Site risk assessment & real‑time data review strategies
- Alignment with TFDA expectations and ICH E6(R3) guidelines
- Transition from routine on‑site to data‑driven, risk‑proportionate monitoring
We collaborate with clinical operations and data management to create RBM plans that improve issue detection, resource allocation, and decision-making speed. This proactive method mitigates operational risks, enhances study performance, and aids in successful TFDA inspections.
Sponsor Oversight Services for Clinical Trial and Compliance
Offering End-to-End Sponsor Oversight for Reliable Trial Execution
Establishing or upgrading a facility requires alignment with the TFDA, PIC/S, GMP, and WHO regulations for product quality and safety. Zenovel offers professional services for setting up and upgrading GMP-compliant manufacturing plants in Taiwan.
- New plant setup—facility planning, infrastructure development, cleanroom classification, HVAC validation, equipment qualification (IQ/OQ/PQ), and QMS integration.
- Existing plant upgradation—modernization, gap closure, contamination control, process optimization, and alignment with TFDA, PIC/S, and WHO GMP standards.
- Regulatory readiness – preparation for TFDA and international GMP inspections.
Zenovel integrates engineering and regulatory expertise to improve operational efficiency, minimize compliance risks, and achieve sustainable manufacturing excellence, offering reliable support for pharmaceutical plant setups and GMP upgrades in Taiwan.
Good Manufacturing Practice (GMP) Services for Pharma Compliance
Ensuring Pharma Compliance with Expert GMP Services in Taiwan
Taiwan’s pharmaceutical manufacturing sector is governed by the TFDA, which adheres to PIC/S GMP standards that align with WHO guidelines. Compliance with GMP is vital for ensuring product quality and patient safety. Zenovel offers GMP Services in Taiwan to aid pharmaceutical companies in maintaining these high standards and regulatory compliance.
Our Services:
- GMP audits & quality system (QMS) support – design, review, and continuous improvement.
- Deviation management, CAPA implementation & documentation control.
- Inspection readiness – gap analysis, mock TFDA inspections, and remediation planning.
- Alignment – TFDA, PIC/S GMP, WHO GMP, and global standards.
Zenovel assists manufacturers in identifying operational gaps, enhancing quality processes, and achieving inspection-ready status, emphasizing product consistency, regulatory compliance, and operational excellence. Partner with us for reliable GMP compliance and pharmaceutical quality support in Taiwan.
GMP Audit Services for Manufacturing Quality Assurance
Strengthening Quality Systems with Expert GMP Audits
Rigorous GMP audits are critical for ensuring product quality, patient safety, and regulatory compliance, such as TFDA, which adheres to PIC/S GMP standards that align with WHO GMP and international guidelines. Zenovel offers expert GMP Audit Services in Taiwan to assist pharmaceutical manufacturers in upholding these high standards and maintaining inspection readiness.
- Comprehensive GMP audits—evaluation of manufacturing facilities, quality systems (QMS), documentation control, batch records, and CAPA effectiveness.
- Supplier & internal audits—vendor quality systems, risk assessments, and root cause analysis.
- Inspection readiness—gap analysis, mock TFDA audits, and remediation planning.
- Alignment – TFDA, PIC/S GMP, WHO GMP, and global standards.
Zenovel provides professional GMP audit and manufacturing compliance support in Taiwan, helping to identify compliance gaps, strengthen quality management, and reduce regulatory risks for consistent product quality and successful TFDA inspections.
Pharma Plant Setup & Upgradation Services for GMP-Compliant Manufacturing
Building GMP‑Compliant Manufacturing Facilities with Expert Pharma Plant Setup & Upgradation in Taiwan
Building manufacturing facilities requires strict regulatory (TFDA) compliance to ensure product quality, patient safety, and inspection readiness. Zenovel offers professional services for Pharma Plant Setup and Upgradation in Taiwan to assist companies in creating efficient, GMP-compliant operations.
- New plant setup – facility planning, cleanroom classification, HVAC validation, equipment qualification (IQ/OQ/PQ), and QMS integration.
- Existing plant upgradation – modernization, gap closure, contamination control, process optimization.
- Alignment – TFDA, PIC/S GMP, WHO GMP, and global standards.
Zenovel integrates engineering expertise with regulatory knowledge to improve operational efficiency, mitigate compliance risks, and maintain long-term manufacturing excellence, offering trusted support for pharma plant setup and GMP upgrades in Taiwan.
Pre-Inspection Readiness Services for GMP Compliance
Ensuring Confident Regulatory Inspections with Pre‑Inspection Readiness Services for GMP Compliance in Taiwan
TFDA enforces PIC/S GMP standards, aligned with WHO guidelines. Regulatory inspections are crucial; poor preparation risks findings, production delays, or license suspensions. Zenovel offers Pre-Inspection Readiness Services in Taiwan to assist pharmaceutical manufacturers in preparing for TFDA inspections and GMP audits.
- Gap analysis – evaluation of quality systems, production processes, and documentation.
- Mock TFDA-style inspections—simulate real regulatory scrutiny.
- Audit trail & CAPA system evaluation.
- Compliance training—staff preparedness and real-time response strategies.
We help organizations identify operational weaknesses, implement corrective actions, and strengthen quality assurance practices before formal evaluations.
Clinical & Scientific Expert Services for Drug Development
Driving Drug Development Success with Clinical & Scientific Expertise in Taiwan
Taiwan’s regulatory framework, overseen by the TFDA, requires rigorous scientific and clinical planning. TFDA enforces ICH E6(R3) Good Clinical Practice standards, making expert guidance essential for navigating complex drug development pathways.
Zenovel delivers specialized Clinical & Scientific Expert Services in Taiwan to support pharmaceutical companies, biotech organizations, and CROs across all stages of development.
- Clinical development strategy & protocol design – tailored to TFDA, ICH, and global benchmarks.
- PK/PD modeling & translational science support – bridging preclinical insights to clinical outcomes.
- Biomarker strategy, endpoint selection & study optimization – enhancing trial success rates.
- Regulatory scientific consulting – for TFDA submissions and international filings (FDA, EMA).
We collaborate with your clinical, regulatory, and R&D teams to transform scientific challenges into actionable development plans, reducing uncertainty and accelerating timelines.
Partner with Zenovel for trusted clinical and scientific consulting support in Taiwan.
Medical & Scientific Writing Services for Regulatory Success
Ensuring Regulatory Success with High‑Quality Medical & Scientific Writing in Taiwan
Regulatory submissions require more than accurate data; they demand clear, compliant, and well‑structured documentation that communicates science effectively to reviewers at the TFDA, ICH E6(R3), and related guidelines.
Zenovel delivers professional Medical & Scientific Writing Services in Taiwan to help pharmaceutical companies, CROs, and biotech organizations produce precise, submission‑ready documents.
- Clinical study reports (CSR), protocols & investigator brochures (IB)
- Informed consent forms (ICF) & CTD/eCTD modules
- Pharmacovigilance documents & clinical summaries
- Full alignment with ICH, TFDA, and global regulatory standards
We combine scientific depth with regulatory precision to create clear, audit‑ready documentation that facilitates efficient reviews and accelerates approvals. Our writers act as a seamless extension of your regulatory and clinical teams.
Preclinical Support Services for Early-Stage Drug Development
Advancing Early-Stage Drug Development with Expert Preclinical Support in Taiwan
Bringing a new therapy from discovery to first‑in‑human trials requires robust preclinical evidence. In Taiwan, the TFDA expects nonclinical data to meet ICH guidelines for safety, pharmacology, and toxicology. Zenovel helps biotech and pharmaceutical companies generate reliable, regulatory‑ready preclinical packages.
Our Preclinical Support Services in Taiwan Include:
- In vitro & in vivo studies – toxicology assessment, PK/PD analysis, and safety pharmacology.
- Bioanalytical support & translational research – bridging discovery to clinical application.
- Lead compound optimization & risk identification – improving candidate selection.
- Regulatory documentation—aligned with TFDA, ICH, and global standards (FDA, EMA).
We tailor study designs to reduce delays and costs while ensuring data accuracy. Our integrated approach accelerates your transition from preclinical to clinical phases.
Partner with Zenovel for trusted preclinical research and drug development support in Taiwan.
Regulatory Affairs & Compliance Services for Global Submissions
Navigating Global Approvals with Expert Regulatory Affairs & Compliance Support
Launching products internationally requires strategic regulatory planning and execution that aligns with TFDA requirements, global standards, and local nuances. Effective submission strategies must consider cross-regional expectations.
Zenovel provides professional Regulatory Affairs Services in Taiwan to help pharmaceutical, biotech, and healthcare companies achieve efficient global approvals.
- Regulatory strategy & gap analysis – tailored to TFDA, FDA, EMA, and WHO requirements.
- CTD/eCTD dossier preparation – IND/CTA, NDA/BLA, and post‑approval maintenance.
- Labeling compliance & regulatory intelligence – lifecycle management across markets.
- Submission coordination – ensuring accuracy, consistency, and timely authority communication.
We work alongside your teams to reduce submission risks, accelerate market access, and maintain compliance throughout the product lifecycle.
Dossier Due Diligence Services for Regulatory Accuracy
Ensuring Submission Integrity with Expert Dossier Due Diligence Services
Even a seemingly complete regulatory dossier can hide minor inconsistencies—missing data, misaligned modules, or formatting errors—that delay review by the TFDA or international authorities. Zenovel helps pharmaceutical companies identify and correct these issues before submission.
Our Dossier Due Diligence Services in Taiwan Include the Following:
- CTD/eCTD gap analysis – missing evidence, contradictions, formatting inconsistencies.
- Clinical & CMC data alignment – ensuring coherence across modules.
- ICH guideline compliance – module integration and submission risk assessment.
- Actionable remediation plans – to strengthen dossier quality and approval confidence.
We collaborate with your regulatory, clinical, and CMC teams to enhance clarity and coherence. This proactive approach reduces submission risks, improves quality assurance, and builds confidence during TFDA or global health authority reviews.
eCTD Compilation Services for Global Regulatory Submissions
Streamlining Global eCTD Submissions with Precision and Compliance in Taiwan
The electronic Common Technical Document (eCTD) is the standard format for regulatory submissions to the Taiwan Food and Drug Administration (TFDA) as well as to international authorities like the FDA, EMA, and WHO. Accurate compilation is critical to avoid validation errors, rejection, or approval delays.
Zenovel delivers professional eCTD Compilation Services in Taiwan to help pharmaceutical and biotech companies produce compliant, error‑free electronic submissions.
- Document formatting & module‑wise structuring – aligning with TFDA, ICH, and global guidelines.
- Hyperlinking, validation & publishing – ensuring technical acceptance by regulatory portals.
- CTD to eCTD conversion & lifecycle management – for IND, NDA, ANDA, and BLA filings.
- Submission readiness – full compliance with evolving eCTD, ICH, and PIC/S requirements.
We prioritize accuracy and efficiency, minimizing errors and reducing review timelines. Our expertise strengthens data integrity and accelerates approval pathways.
Environmental Risk Assessment Services for Regulatory Compliance
Meeting Global Environmental Standards with Expert Risk Assessment in Taiwan
Environmental safety has become crucial for pharmaceutical regulatory approvals globally. The TFDA mandates sponsors to assess the environmental impact of active pharmaceutical ingredients and manufacturing processes. Conducting early environmental risk assessments (ERA) can prevent submission delays and enhance sustainability. Zenovel offers Environmental Risk Assessment Services in Taiwan, assisting pharmaceutical and biotech firms in meeting TFDA requirements and adhering to international standards like ICH guidelines and the EU ERA framework.
- Phase I & Phase II environmental assessments – initial and refined risk evaluations.
- PEC/PNEC calculations & exposure modeling – predicting environmental concentrations and effects.
- Ecotoxicity evaluation & regulatory dossier preparation – aligned with submission requirements.
- Integration with global submission strategies – for TFDA, EMA, FDA, and WHO.
Integrating ERA early in development reduces approval risks, supports responsible manufacturing, and enhances regulatory confidence. Zenovel delivers scientifically robust documentation for global submissions and lifecycle compliance.
EU QP Support Services for Batch Release Compliance
Facilitating EU Market Access with Expert QP Batch Release Support in Taiwan
For Taiwanese pharmaceutical companies, QP certification is required for batch release in the EU, ensuring compliance with EU GMP Annex 16. The Taiwan Food and Drug Administration (TFDA) aligns its GMP standards with international norms, aiding companies in obtaining EU approval. Zenovel offers EU QP Support Services in Taiwan to help manufacturers meet these regulatory requirements and secure timely batch certification.
- Batch record review & GMP compliance verification – against EU GMP and PIC/S standards.
- Deviation assessment & quality documentation evaluation.
- Coordination with EU Qualified Persons—for final certification and release.
- Alignment with EU GMP Annex 16 and global regulatory expectations.
- Support under TFDA export guidelines and WHO GMP/PIC/S frameworks.
We minimize approval delays and compliance risks, enabling smooth product distribution across the EU. Zenovel is your trusted partner for compliant batch releases from Taiwan.
Regulatory Gap Analysis Services for Compliance Readiness
Identifying and Closing Compliance Gaps for TFDA and Global Readiness in Taiwan
Regulatory gaps in clinical, non-clinical, or CMC documentation can cause delays in approvals from the TFDA, FDA, EMA, and WHO. Early detection is essential to prevent submission rejections and access delays. Zenovel offers Regulatory Gap Analysis Services in Taiwan to assist pharmaceutical and biotech companies in enhancing compliance and readiness.
- Dossier completeness & data integrity – review of clinical, non‑clinical, and CMC sections.
- SOP compliance & submission readiness – alignment with TFDA, ICH, PIC/S, and WHO standards.
- Gap identification—missing evidence, contradictions, and formatting issues in IND, NDA, ANDA, or BLA applications.
- Actionable remediation plans – prioritized recommendations for compliance optimization.
Zenovel assists sponsors in minimizing approval risks and improving submission quality for TFDA and global authorities. Our structured approach prevents regulatory delays and ensures audit-ready documentation. We offer expertise in regulatory gap analysis and compliance readiness support in Taiwan.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
